Literature DB >> 9220166

Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects.

T Lazzarotto1, P Spezzacatena, P Pradelli, D A Abate, S Varani, M P Landini.   

Abstract

Diagnosis of primary human cytomegalovirus (HCMV) infection is accomplished exclusively by serologic testing. Among the possible methods, the determination of immunoglobulin G (IgG) avidity is one of the least explored. In this work, we used a commercially available kit to test anti-HCMV IgG avidity in 336 serum samples from pregnant women and transplant recipients undergoing virologically proven HCMV primary or nonprimary infections and from latently infected blood donors. Our results demonstrate that the anti-HCMV IgG avidity test differentiates primary from nonprimary HCMV infections in both pregnant women and solid organ transplant recipients. In fact, 88.6% of primary infections and no secondary infections showed low-avidity IgG to HCMV. In particular, low IgG avidity is a marker of primary infection for 18 to 20 weeks after onset of symptoms in both immunocompromised and immunocompetent subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220166      PMCID: PMC170552          DOI: 10.1128/cdli.4.4.469-473.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  24 in total

1.  Correlation between immunofluorescent detection of human cytomegalovirus immediate early antigens in polymorphonuclear leukocytes and viremia.

Authors:  M Grazia Revello; M Zavattoni; E Percivalle; P Grossi; G Gerna
Journal:  J Infect Dis       Date:  1989-07       Impact factor: 5.226

2.  An enzyme labelled nuclear antigen immunoassay for detection of cytomegalovirus IgM antibodies in human serum: specific and non-specific reactions.

Authors:  C M Nielsen; K Hansen; H M Andersen; J Gerstoft; B F Vestergaard
Journal:  J Med Virol       Date:  1987-05       Impact factor: 2.327

Review 3.  Human cytomegalovirus infection: a complex diagnostic problem in which molecular biology has induced a rapid evolution.

Authors:  P D Monte; T Lazzarotto; A Ripalti; M P Landini
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

4.  Evaluation of the CMV-CUBE assay for detection of cytomegalovirus serologic status in marrow transplant patients and marrow donors.

Authors:  C A Gleaves; S F Wendt; D R Dobbs; J D Meyers
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

5.  Pattern of anti-cytomegalovirus IgM antibodies determined by immunoblotting. A study of kidney graft recipients developing a primary or recurrent CMV infection.

Authors:  J Basson; J C Tardy; M Aymard
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

6.  Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity.

Authors:  N K Blackburn; T G Besselaar; B D Schoub; K F O'Connell
Journal:  J Med Virol       Date:  1991-01       Impact factor: 2.327

7.  Measurement of avidity of specific IgG for verification of recent primary rubella.

Authors:  K Hedman; S A Rousseau
Journal:  J Med Virol       Date:  1989-04       Impact factor: 2.327

8.  Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.

Authors:  M P Landini; T Lazzarotto; G T Maine; A Ripalti; R Flanders
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

9.  Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes.

Authors:  W van der Bij; R Torensma; W J van Son; J Anema; J Schirm; A M Tegzess; T H The
Journal:  J Med Virol       Date:  1988-06       Impact factor: 2.327

10.  Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay.

Authors:  S L Nielsen; I Sørensen; H K Andersen
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

View more
  36 in total

1.  Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenic bacteria and maternal immunity.

Authors:  Lenore Pereira; Ekaterina Maidji; Susan McDonagh; Olga Genbacev; Susan Fisher
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy.

Authors:  M Gentile; C Galli; P Pagnotti; P Di Marco; S Tzantzoglou; F Bellomi; M L Ferreri; C Selvaggi; G Antonelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

4.  Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population.

Authors:  Aparecida Y Yamamoto; Marisa Marcia Mussi-Pinhata; Myriam de Lima Isaac; Fabiana R Amaral; Cristina G Carvalheiro; Davi C Aragon; Alessandra K da Silva Manfredi; Suresh B Boppana; William J Britt
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

5.  Cytomegalovirus infection in neonates following exchange transfusion.

Authors:  Atul Kothari; V G Ramachandran; Piyush Gupta
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

6.  Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection.

Authors:  T Lazzarotto; P Spezzacatena; S Varani; L Gabrielli; P Pradelli; B Guerra; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

7.  Performance characteristics of current-generation Immulite 2000 TORCH Assays.

Authors:  A R Centonze; E Tonolli; R Fontana
Journal:  Clin Vaccine Immunol       Date:  2012-11-21

8.  Potential impact of different cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Andrew Brenner; Nancy Pitstick; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

9.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

10.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.